Institut du Cerveau–Paris Brain Institute–ICM, Institut National de la Santé et de la Recherche Médicale (INSERM), CNRS Sorbonne Université Paris France
Auto-generated profile, based on publicly available information
Ann-Sofie De Meulemeester
Institut du Cerveau–Paris Brain Institute–ICM, Institut National de la Santé et de la Recherche Médicale (INSERM), CNRS Sorbonne Université Paris France
Ras GTPase-activating protein-binding proteins 1 and 2 (G3BP1 and G3BP2, respectively) are widely recognized as core components of stress granules (SGs). We report that G3BPs reside at the cytoplasmic surface of lysosomes. They act in a non-redundant manner to anchor the tuberous sclerosis complex (TSC) protein complex to lysosomes and suppress activation of the metabolic master regulator mechanistic target of rapamycin complex 1 (mTORC1) by amino acids and insulin. Like the TSC complex, G3BP1 deficiency elicits phenotypes related to mTORC1 hyperactivity. In the context of tumors, low G3BP1 levels enhance mTORC1-driven breast cancer cell motility and correlate with adverse outcomes in patients. Furthermore, G3bp1 inhibition in zebrafish disturbs neuronal development and function, leading to white matter heterotopia and neuronal hyperactivity. Thus, G3BPs are not only core components of SGs but also a key element of lysosomal TSC-mTORC1 signaling.
In recent years there has been extensive research on malformations of cortical development (MCDs) that result in clinical features like developmental delay, intellectual disability, and drug-resistant epilepsy (DRE). Various studies highlighted the contribution of microtubule-associated genes (including tubulin and kinesin encoding genes) in MCD development. It has been reported thatde novomutations inKIF2A, a member of thekinesin-13family, are linked to brain malformations and DRE. Although it is known that KIF2A functions by regulating microtubule depolymerization via an ATP-driven process,in vivoimplications ofKIF2Aloss of function remain partly unclear. Here, we present a novelkif2aknock-out zebrafish model, showing hypoactivity, habituation deficits, pentylenetetrazole-induced seizure susceptibility and microcephaly, as well as neuronal cell proliferation defects and increased apoptosis. Interestingly,kif2a−/−larvae survived until adulthood and were fertile. Notably, ourkif2azebrafish knock-out model demonstrated many phenotypic similarities toKIF2Amouse models. This study provides valuable insights into the functional importance ofkif2ain zebrafish and phenotypical hallmarks related toKIF2Amutations. Ultimately, this model could be used in a future search for more effective therapies that alleviate the clinical symptoms typically associated with MCDs.
The Rift Valley fever virus (RVFV) is listed by the WHO as priority disease and causes haemorrhagic fever, encephalitis, and permanent blindness. To study RVFV pathogenesis and identify small-molecule antivirals, we established a novel in vivo model using zebrafish larvae. Pericardial injection of RVFV resulted in ~ 4 log 10 viral RNA copies/larva, which was inhibited by antiviral 2′-fluoro-2′-deoxycytidine. The optical transparency of the larvae allowed detection of RVFV eGFP in the liver and sensory nervous system, including the optic tectum and retina, but not the brain or spinal cord. Thus, RVFV-induced blindness likely occurs due to direct damage to the eye and peripheral neurons, rather than the brain. Treatment with JAK-inhibitor ruxolitinib, as well as knockout of stat1a but not stat1b , enhanced RVFV replication to ~ 6 log 10 viral RNA copies/larva and ultra-bright livers, although without dissemination to sensory neurons or the eye, hereby confirming the critical role of stat1 in RVFV pathogenesis.